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Background: There is a need for preventative asthma maintenance therapy that provides lasting
bronchoprotection against allergen provocation. Fluticasone furoate (FF) is a novel inhaled once-daily corticosteroid,
being investigated as monotherapy for asthma and in combination with vilanterol (VI), a novel inhaled once-daily
long-acting beta-agonist, for asthma and chronic obstructive pulmonary disease.
Methods: In a crossover study of 52 subjects with mild asthma, FF/VI 100/25mcg and FF 100 dosed once-daily in
the evening for 28 days were compared with placebo to evaluate their capacity to provide bronchoprotection
against the early asthmatic response (EAR) stimulated by an inhaled allergen challenge. Bronchoprotection was
assessed by change from post-saline baseline in weighted mean (wm) forced expiratory volume in 1 s (FEV1) for the
first 2 h post-allergen challenge, which was on Day 29 (22–23 h post final dose on Day 28). The EAR was also
assessed using maximum percent decrease from post-saline baseline and minimum absolute FEV1; the incidence of
adverse events was a secondary endpoint.
Results: FF/VI 100/25 and FF 100 both provided significant bronchoprotection against the EAR for all endpoints
assessed. For wmFEV1 over the first 2 h post-allergen challenge, a 162 mL (95% CI, 87 to 237 mL) difference was
observed between placebo and FF 100, while a 145 mL (95% CI, 69 to 222 mL) difference was observed between
placebo and FF/VI 100/25 treatment. No difference between active treatments was observed (−17 mL; 95% CI, –91
to 57 mL). Both treatments were well tolerated.
Conclusions: FF 100 alone and in combination with VI 25 provides significant bronchoprotection against the EAR
in subjects with mild asthma. That this protection is provided at the trough of dosing, i.e. 23 h post last dose,
supports the utility of FF 100 and FF/VI 100/25 as viable once-daily therapies.
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The link between asthma and atopy is well established
[1]. Many asthmatic subjects exhibit an asthmatic re-
sponse (AR) to aeroallergens [2-4] that can lead to a re-
duction in patients’ quality of life and be an important
trigger of exacerbations [5]. Experimental allergen chal-
lenge studies have shown the AR to comprise two tem-
poral events, of which some subjects experience both
while others experience only one [6]. The early AR
(EAR) starts about 20 min after exposure to allergen in a
sensitized subject and is typified by a rapid decline in
lung function, which recovers within 2–3 h. It has been
shown to be most associated with immunoglobulin E-
mediated mast cell activation and release of spasmogenic
mediators [6-8]. The late AR (LAR) consists of a subse-
quent, less acute, decline in lung function starting be-
tween 2–4 h post-exposure, which is most severe at
8–12 h, and which may not be fully recovered by 24 h.
Experimentally, the LAR has been shown to be charac-
terised by an inflammatory infiltrate; subjects who de-
velop the LAR also exhibit increased airway hyper-
responsiveness (AHR) for several days [3-8].
The LAR, when initiated by allergen challenge, is recog-
nized as a valid clinical model of asthma, and has been
widely employed to test the mechanism of the response
[3,4], and the efficacy of interventions [9-11]. The LAR is
regarded as more clinically important than the EAR [12]
and is also more amenable to currently available therapy,
as attenuation of the LAR is consistently demonstrated
with ICS [3]. The EAR nonetheless represents an import-
ant clinical event in sensitized asthmatic subjects, as it can
result in a significant decline in lung function, albeit of a
relatively short duration, and can also contribute to wor-
sened AHR if it occurs in combination with the LAR [3].
Published literature suggests that regular therapy with ICS
can reduce the early asthmatic response (EAR) [13,14]
though this has not been consistently observed [10] sug-
gesting a need for improved therapies. The goal of asthma
management is to achieve optimal control, which includes
normal lung function and the need to use rescue therapy
less than twice a week [1]. Exposure to aeroallergens may
result in an EAR in sensitized individuals, which in turn
may lead to symptoms and necessitate the use of rescue
medication. As such it is important that the EAR, in
addition to the LAR, be limited or abrogated by mainten-
ance therapy.
Current maintenance therapy for asthma typically
comprises an inhaled corticosteroid (ICS), supplemen-
ted, where additional control is required, with additional
controller medications, the preferred add-on therapy
being an inhaled long-acting beta-agonist (LABA). Fluti-
casone furoate (FF) is a novel once-daily ICS that is effi-
cacious and safe in mild-to-moderate asthma [15-18].
Vilanterol (VI), a novel inhaled once-daily LABA alsoexhibits efficacy and safety in persistent asthma [19-21].
This study sought to explore the impact of the novel
ICS, FF, on the EAR at the trough of once-daily dosing
(i.e. 22–23 h post-dose), and to determine whether
addition of VI to FF had any additional effect. This ap-
proach differs from the majority of allergen-response
studies, where the efficacy of treatment is assessed in the




This was a multi-centre, randomised, double-blind,
placebo-controlled, 3- period crossover study conducted
at two sites in the UK, one in Germany and one in New
Zealand. Recruited subjects were screened within 14 to
42 days before the first dose of study treatment, with a
run-in period of at least 14 days before the first dose of
study medication. During screening, at which time the
subject’s specific allergen and dose of allergen were
established (see “Allergen challenge” section in Meth-
ods), and after successful completion of the run-in
period, subjects were randomised by RandAll (GlaxoS-
mithKline validated internal randomisation software) to
1 of 6 treatment sequences, each comprising 3 treatment
periods. Over the 3 periods, each subject took 28 days of
once-daily inhaled study treatment (FF 100mcg, FF/VI
100/25mcg or placebo) via a novel dry-powder inhaler
each evening between 6 pm and 8 pm. Subjects were
dosed in the evening on the basis of evidence that FF
once-daily evening dosing resulted in similar efficacy to
twice-daily dosing at half the evening dose, while morn-
ing dosing although effective resulted in numerically
smaller improvements [18]. On Day 29 subjects under-
went an inhaled allergen challenge 22–23 h after their
Day 28 treatment, thus the challenge was initiated be-
tween 4 pm and 7 pm. The morning following the chal-
lenge subjects were sent home providing their FEV1 was
restored to >90% of post-saline baseline. A washout
period of 21–35 days was required between treatment
periods. Following completion of the last treatment
period, there was a follow-up period of 7–21 days.
Allergen challenge
The subject-specific allergen was chosen based on the
relative size of awheal reaction to cat hair, house dust
mite and grass pollen allergens. The skin prick test was
administered either at screening or within 12 months
before starting the study. The dose of allergen used was
determined during screening using an allergen challenge
where subjects were required to inhale increasing doses
of allergen using a dosimeter and the effect on FEV1 was
measured after each inhalation. Prior to the allergen
challenge, a post-saline FEV1 was obtained following a
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an EAR was determined by a fall in FEV1 of ≥20% from
the post-saline baseline value between 5 and 30 min
after the final concentration of allergen. The presence or
absence of the LAR was not determined. On Day 29 of
each treatment period, subjects underwent inhaled aller-
gen challenges 22–23 h (between 4 pm and 7 pm) after
their Day 28 treatment using a bolus dose of allergen,
which was calculated by totalling all the allergen admi-
nistered during the screening allergen challenge. Sub-
jects were required to stay in the unit overnight for
reasons of safety and were sent home the following day
providing their FEV1 was restored to >90% of the post-
saline baseline value. A detailed description of the
screening and bolus allergen challenge procedures used
in this study is provided in Additional file 1.
Patients
To be eligible for study entry, subjects were required to
be aged 18–65 years and to have a documented history
of bronchial asthma for at least 6 months, managed with
intermittent inhaled short-acting beta-agonist (SABA)
therapy only. Subjects were required to exhibit a pre-
bronchodilator FEV1 of >70% at screening, and had to
show a methacholine challenge PC20 of <8 mg/mL at
screening, or previous adenosine monophosphate or his-
tamine challenge PC20 values of <60 mg.mL
-1 or
<8 mg.mL-1, respectively, within the last 6 months. Sub-
jects had to be current non-smokers who had not used
any tobacco products in the 6-month period preceding
the screening visit and who had a pack history of ≤10
pack years (number of pack years = number of cigarettes
per day/20 x number of years smoked). In addition, sub-
jects were required to demonstrate a positive skin prick
test (defined as wheal ≥3 mm, relative to the negative
control) to one or more of a range of allergens. At
screening, subjects were required to exhibit an EAR to
inhaled allergen challenge (see Additional file 1). Finally,
to commence each treatment period, subjects were
required to exhibit an FEV1 value within 10% of the
value exhibited at screening. Exclusion criteria from the
study included the presence of a respiratory tract infec-
tion or asthma exacerbation within 4 weeks before the
administration of the first study dose, and a history of
life-threatening asthma, defined as an asthma episode
that required intubation and/or any of hypercapnea, re-
spiratory arrest and hypoxic seizures. Subjects symptom-
atic with hayfever at screening, or predicted to
experience hayfever during days 21 to 29 of any treat-
ment period, were also excluded, as were those with
known hypersensitivity to corticosteroids or beta-
agonists. All patients provided written informed consent,
and the study was approved by local institutional review
boards and regulatory authorities, as appropriate.Outcome measures
The primary objective was to evaluate the bronchopro-
tective effect of treatment with repeated inhaled doses of
FF/VI 100/25 and FF 100 compared with placebo on the
EAR to inhaled allergen 22–23 h post-dose in subjects
with mild asthma. The secondary objective was to com-
pare the effect of FF/VI 100/25 with that of FF 100.
These objectives were assessed through the primary end-
point of weighted mean (wm) change from post-saline
baseline in FEV1 between 0–2 h after the allergen chal-
lenge on treatment period Day 29 (22–23 h post-
treatment on Day 28). The secondary efficacy endpoints
were: (i) maximum percentage decrease from post-saline
baseline (Day 29) between 0–2 h, and (ii) minimum
FEV1 (i.e. maximum absolute decrease from post-saline
baseline [Day 29], hereafter referred to as maximum ab-
solute decrease from post-saline baseline) over the same
time period. FEV1 was also determined on Day 1 of each
treatment period, pre-dose and on Day 29 of each treat-
ment period prior to initiation of the allergen challenge.
Summary statistics for these evaluations are presented in
results. In addition, the incidence of treatment-emergent
adverse events (AEs) was assessed as a secondary end-
point. The occurrence of AEs was monitored from Day
1, and serious AEs (SAEs) from screening, through to
the end of follow-up. Clinical laboratory and vital signs
were assessed during screening, at pre-dose on Day 1,
and before the allergen challenge on Day 29 of each
treatment period. A 12-lead ECG was recorded during
screening only, and a physical examination was done
during screening and again during follow-up.
Statistical analysis
This study was exploratory in nature, therefore no for-
mal hypothesis testing was performed, nor was the study
powered to detect treatment differences; instead point
estimates and 95% confidence intervals (CI) for treat-
ment differences for each endpoint were calculated and
the study was designed to estimate the mean treatment
difference between treatment groups with a certain de-
gree of precision. A within-subject variability of 191 mL
(estimated from a previous study) and a sample size of
36 subjects would ensure the half-width of the 95% CI
for the treatment difference was no larger than 88 mL.
Approximately 42 subjects were to be randomised to
achieve 36 completed subjects (assuming a 10% failure
rate). The intent-to-treat (ITT) population comprised all
randomised subjects who received at least one dose of
study medication and constituted the primary popula-
tion for all efficacy and safety analyses. Only protocol
deviations that were considered to affect efficacy were
excluded from the efficacy analyses. The primary and
secondary efficacy endpoints were analysed using a
mixed-effects analysis of covariance (ANCOVA) model,
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baseline, period-level baseline, country, sex and age and
subject fitted as a random effect.
Results
Subject disposition and demographics
A total of 52 subjects were randomised and were
included in the ITT population overall; of these subjects,
51 took part in each of the treatment periods. The num-
ber of subjects with one or more protocol deviations is
illustrated in Figure 1: 45 subjects on placebo, 49
patients on FF and 46 on FF/VI did not have protocol
deviations that were deemed to affect efficacy so were
included in the efficacy analyses. Two subjects were
withdrawn from the study, one due to a SAE during the
FF 100 treatment washout; and one subject withdrew
consent during the FF/VI 100/25 treatment period.
The mean subject age was 35.4 years, 35% were fe-
male, and 92% were of white race (Table 1). Baseline
lung function showed a mean FEV1 percent predicted of
89.71% (SD= 8.85%). Ten subjects (19%) were challengedFigure 1 Study CONSORT Diagram. FF = fluticasone furoate; ITT = intent-twith cat dander/hair, 23 subjects (44%) with grass pollen,
and 19 subjects (37%) with house dust mite. Salbutamol
was the most frequently reported concomitant medica-
tion. During the study, 69, 71, and 61% of subjects
reported using salbutamol in the placebo, FF 100 and
FF/VI 100/25 treatment periods, respectively, and 69%
reported salbutamol use during the washout periods.
Efficacy
A time course of absolute FEV1 from pre-dose on Day 1
to 0–2 h post challenge on Day 29 shows an improve-
ment of lung function with active treatment and the
characteristic decline in lung function of the EAR fol-
lowing allergen challenge (Figure 2a). With placebo
treatment, the greatest reduction in FEV1 was observed
between 15 and 30 min post challenge, from which point
FEV1 increased but had not returned to the post-saline
baseline level at 120 min post challenge. Relative to pla-
cebo, the immediate decline in lung function after aller-
gen challenge was significantly reduced with FF 100 or
FF/VI 100/25 treatment (Figure 2b).o-treat population; VI = vilanterol.
Figure 2 Summary of the FEV1 time course of mean absolute FEV1 fro
FEV1 change from allergen challenge post-saline baseline measure (B
allergen challenge initiated on Day 29 (between 4 pm and 7 pm). FEV1 = fo
SE = standard error; VI = vilanterol. Not all subjects contributed data to all ti
Table 1 Demographics and Baseline Characteristics
(intent-to-treat population)
Demographics (N= 52a)
Age, mean (SD) 35.4 (8.63)
Female, % 35
BMI, kg/m2, mean (range) 25.94 (18.9–33.6)
White race, % 92
Lung function
Pre-bronchodilator FEV1, L, mean (SD) 3.52 (0.713)
Pre-bronchodilator FEV1% Pred., mean (SD) 89.71 (8.848)
a51 subjects took part in each of the treatment periods. BMI = body mass
index; FEV1 = forced expiratory volume in 1 s; L = litres; SD= standard deviation.
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sured by all efficacy endpoints was observed with both
treatments relative to placebo (Table 2). Mean treatment
differences showed a 162 mL reduced decline of the
wmFEV1 (over 0 to 2 h post-allergen challenge) for FF
100 vs. placebo and a 145 mL reduced decline of
wmFEV1 after treatment with FF/VI 100/25 vs. placebo.
No significant difference was seen between the active
treatments (Table 2). The adjusted means for the
wmFEV1 change from post-saline baseline were
–372 mL (SE = 55.7), –210 mL (SE = 54.9) and –227 mL
(SE = 55.0) with placebo, FF 100 and FF/VI 100/25, re-
spectively (Additional file 2: Figure S1a).m Day 1 pre-dose to 2 h post allergen challenge (A) and mean
). Therapy was dosed between 6 pm and 8 pm on Days 1–28 and the
rced expiratory volume in 1 s; FF = fluticasone furoate; L = litres;
me points.
Table 2 Statistical analysisa of treatment differences in
change from post-saline baseline (intent-to-treat
population)
Treatment difference 95% CI
wmFEV1 (L)
FF – placebo 0.162 0.087, 0.237
FF/VI – placebo 0.145 0.069, 0.222
FF/VI – FF −0.017 −0.091, 0.057
Max. percent decrease (%)
FF – placebo 10.951 8.053, 13.848
FF/VI – placebo 11.785 8.849, 14.721
FF/VI – FF 0.834 −2.010, 3.678
Max. absolute decrease in FEV1 (L)
FF – placebo 0.330 0.232, 0.429
FF/VI – placebo 0.331 0.231, 0.431
FF/VI – FF 0.001 −0.096, 0.097
aPopulation sizes analysed: placebo, n = 45; FF, n = 49; FF/VI, n = 46. Efficacy
endpoints were analysed using a mixed-effects analysis of covariance
(ANCOVA) model, with fixed effects of treatment, period, subject-level
baseline, period-level baseline, country, sex and age and subject fitted as a
random effect.
CI = confidence interval; FEV1 = forced expiratory volume in 1 s; FF = fluticasone
furoate; L = litres; VI = vilanterol; wm=weighted mean.
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line in FEV1 over time is shown in Figure 3, and the
treatment differences between placebo, FF 100 and FF/
VI 100/25 are summarised in Table 2. Significant reduc-
tion in the maximum percentage decrease from post-
saline baseline was observed with each active treatment
relative to placebo (11%), and no significant difference
was observed between the FF 100 and FF/VI 100/25
treatments. The adjusted means for the maximumFigure 3 Summary of the time course of maximum percentage chang
and 8 pm on Days 1–28 and the allergen challenge initiated on Day 29 (be
FF = fluticasone furoate; SE = standard error; VI = vilanterol. Not all subjects cpercent change from post-saline baseline in the placebo,
FF 100 and FF/VI 100/25 arms were −24.991% (SE =
2.0736),–14.040% (SE = 2.0435) and −13.206% (SE =
2.0491) (Additional file 2: Figure S1b).
Differences in the maximum absolute FEV1 decrease
from post-saline baseline between each active treatment
and placebo were significant, but not significant between
active treatments (Table 2). The adjusted means for the
maximum FEV1 absolute decrease from post-saline base-
line in the placebo, FF 100 and FF/VI 100/25 arms were
–809 mL (SE = 77.5), –479 mL (SE = 76.5) and –478 mL
(SE = 76.7) (Additional file 2: Figure S1c).
Although it was not a study endpoint, FEV1 was assessed
pre-dose on Day 1 and prior to the allergen challenge on
Day 29. Over the 28 days of dosing, a mean decline of
82.4 mL (SD=237 mL) was observed with placebo, while
increases in FEV1 of 146.4 mL (SD=239 mL) and
279.4 mL (SD=264 mL) were observed with FF 100 and
FF/VI 100/25, respectively.
Safety
On-treatment AEs were similar between the study arms,
with any AE being reported in 39% of subjects during
the placebo treatment period, in 43% of subjects during
the FF 100 treatment period, and in 35% of subjects dur-
ing the FF/VI 100/25 treatment period. Twenty-seven
percent of on-treatment AEs in the placebo and FF 100
arms were deemed to be related to study treatment, and
29% of events were deemed to be related to study treat-
ment for the FF/VI 100/25 treatment. Headache was the
most frequently reported AE (Table 3). AEs occurring at
a frequency of greater than 3%, and only in the active
treatment arms, were: mouth ulceration and dysphonia,e in post-saline baseline FEV1. Therapy was dosed between 6 pm
tween 4 pm and 7 pm). FEV1 = forced expiratory volume in 1 s;
ontributed data to all time points.
Table 3 Most frequent on-treatment adverse events (≥3%
any treatment group) intent-to-treat population






Headache 11 (22) 5 (10) 9 (18)
Oropharyngeal
pain
2 (4) 2 (4) 2 (4)
Nasopharyngitis 2 (4) 0 3 (6)
Cough 3 (6) 0 1 (2)
Chest discomfort 0 0 3 (6)
Mouth
ulceration
2 (4) 2 (4) 0
Nausea 2 (4) 0 2 (4)
Dysphonia 2 (4) 2 (4) 0
Hot flush 0 2 (4) 0
Seasonal allergya 2 (4) 0 0
aOne subject (2%) had seasonal allergy, reported as allergic rhinitis, during
each treatment period.
FF = fluticasone furoate; VI = vilanterol.
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tive treatment. Vital signs, clinical chemistry and haema-
tology were similar between all three treatments, and no
abnormalities of clinical importance were observed.
One subject withdrew during the study due to an SAE,
which occurred 4 days after the last dose in the FF 100
treatment period. This subject was provisionally diag-
nosed with moderate (grade 2) Still’s disease. Six weeks
later, the subject was hospitalised. A diagnosis of histio-
cytic necrotising lymphadenitis (Kikuchi’s Disease) was
made based on histology of an excised lymph node.
Tapered prednisolone treatment, initiated at 60 mg per
day, has been successful.
Discussion
Both FF/VI 100/25 and FF 100 clinically and significantly
suppress the EAR to an allergen challenge relative to
placebo. This is supported by significant differences be-
tween active treatment and placebo being observed in (i)
the wm change in FEV1 from post-saline baseline, (ii)
the maximum percentage decrease in FEV1 from post-
saline baseline, and (iii) the maximum absolute decrease
in FEV1 from post-saline baseline. No major safety sig-
nals were observed in this crossover study, and in the
one subject who discontinued due to an SAE, the event
subsequently resolved.
Bronchoprotection against the early and late allergic re-
sponse is a part of asthma control [1], and is one of the
characteristics that should be expected of any asthma
maintenance therapy – especially as increased levels of
aeroallergens such as grasses, house dust mite or dander
are associated with increased rates of asthma exacerbation
and hospitalisation [5]. When the allergic response (typic-
ally the LAR) is used as a model to test the extent ofbronchoprotection provided by an intervention, the test is
typically conducted shortly after dosing of the intervention
[10]. This approach is rational when seeking to establish
whether a novel intervention is capable of providing
bronchoprotection, given the strong negative predictive
power of the allergen challenge model [3]. However, when
considering an intervention of known efficacy, the key time
to test the bronchoprotective capacity of an intervention is
at the trough of dosing, as this provides evidence of the
sustained effect of the intervention, as has been investi-
gated for the twice-daily dosed ICSs fluticasone propionate
and budesonide [22,23]. In the present study, the allergen
challenge was initiated on Day 29, 22–23 h after the final
dose of study medication, and as such total ablation of the
EAR was not expected. Nevertheless, the results showed a
clear and significant effect on the EAR after 28 days once-
daily therapy with either FF 100 or FF/VI 100/25 yielding
an approximate 150 mL reduction in the extent of the
EAR over the first 2 h post-challenge relative to placebo.
That this effect was also seen for maximum percentage de-
crease (~11%) and maximum decrease in FEV1 from post-
saline baseline (~330 mL) suggests that even at the trough
of once-daily dosing, FF 100 and FF/VI 100/25 continue to
exhibit protection from allergen-induced EAR.
The secondary objective of this study was to assess the
bronchoprotective effect of FF/VI 100/25 relative to FF
100. Previously it has been shown that a LABA/ICS
combination resulted in significantly greater attenuation
of the EAR compared to ICS alone [10], although in that
study, the challenge was not conducted at the end of the
dosing interval. The additional attenuation of the re-
sponse provided by the LABA over the ICS response has
been ascribed to ‘functional antagonism’ of the EAR/
LAR by the bronchodilatory effect of the LABA [10].
LABAs have also demonstrated protection in exercise-
induced asthma models [24,25] where the challenge was
initiated at or near the end of the dosing period, suggest-
ing that functional antagonism can persist throughout
the dosing period. In the present study, no additional ef-
fect on suppression of the EAR was observed with FF/VI
100/25 relative to FF 100. There are a number of poten-
tial reasons for this observation. In the first instance, the
mean pre-bronchodilator FEV1 of the subjects recruited
into this study was almost 90%; therefore it is conceiv-
able that any functional antagonism provided by VI
would be obscured by the near normal baseline lung
function, which was further improved after 28 days of
therapy with both FF 100 and FF/VI 100/25. In the sec-
ond instance, as the allergen challenge was conducted
on Day 29 at trough drug levels, it is possible that any
additional improvement in FEV1 provided by VI through
functional antagonism had abated at that time point. It
would be of interest to explore, in a further study, the
EAR at 6, 12 or 18 h following dosing to investigate
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the duration of this effect. However, studies assessing
bronchodilation by VI over time have shown a 24h dur-
ation of effect of VI on lung function demonstrated by
improvements relative to placebo in FEV1 measured at
24 h post-dose of 121 mL after 28 days [19] and 125 mL
after 7 days [21] of dosing in subjects with persistent
asthma receiving concomitant ICS.
As with all allergen challenge studies, there were
strengths and limitations associated with this study. The
study was limited in that only effects on the EAR were
investigated, and as patients were only assessed for the
presence of the EAR at screening it is not possible to know
how many of those recruited were single versus dual
responders. Also, while the effect of FF 100 and FF/VI 100/
25 was assessed relative to placebo, the effect of VI 25mcg
was not. However, a separate study (NCT01128595) investi-
gating the effects of FF and VI alone and in combination
on the EAR and LAR at 1 h post-dose in confirmed dual
responders has been completed and will be reported else-
where. A further limitation is that subjects were receiving
SABA only at enrolment so the next treatment step,
according to the GINA guidelines, is low-dose ICS rather
than an ICS-LABA combination [1]. However, the response
to inhaled allergen can be thought of as simulating the need
to increase therapy, by experimentally destabilising asthma,
and, therefore, mimicking a patient in need of ICS/LABA
therapy. The data from this study are strengthened by a
number of factors: firstly, the challenge was conducted on
Day 29 of each treatment period (i.e. at the end of the dos-
ing interval, 22-23 h post-dose on Day 28). Despite the im-
portance of asthma control throughout the dosing interval,
testing at the time of minimal drug effect has been infre-
quently studied in challenge models [22,23]; secondly, the
design of the study, particularly the option to extend the
washout period and the careful selection of subjects meant
that the study was able to be conducted through the hay
fever season (in the UK and Germany). Consequent to this,
one subject reported two occurrences of seasonal allergy as
an AE during the FF 100 treatment period, on days 2 and
23. One further subject reported allergic rhinitis on days
23, 21 and 4 of treatment periods 1, 2 and 3, respectively. It
is possible that the AEs on days 21 and 23 may have influ-
enced the primary endpoint; however, given the overall in-
cidence of these events any effect would have been small.
Conclusions
In conclusion, FF 100 and FF/VI 100/25 – doses that
have been progressed to phase III trials – inhaled daily
over 28 days provide significant and clinically relevant
bronchoprotection against the EAR relative to placebo.
That this protection occurs at the end of the dosing
interval suggests true 24 h activity of both FF 100, and
the combination of FF/VI 100/25. Consequently bothhave the potential to reduce the symptoms associated
with the allergic response in atopic asthma subjects, and
to improve asthma control and quality of life.
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Additional file 1: Supplement 1. Allergen Challenge, detailed method [26].
Additional file 2: Supplement 2. Change from allergen challenge post-
saline baseline (least squares means, 95% CI) for wmFEV1 (a), maximum %
FEV1 decline (b) and maximum absolute FEV1 decline (c).
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